News
-
Telix APAC boss predicts local pressure, MFN workarounds
- Fri Aug 21
Telix VP Adrian Dunstan unveils ways companies hope to skirt US reference pricing while predicting growing pressure for country leaders to launch successfully, or be told to leave.
Read more -
ANZ pharmas strengthen leadership teams
- Fri Aug 21
Biogen, MSD and Lundbeck have taken on senior people this month as top executives move around and companies have their choice of talent.
Read more -
Sobi tops with rare disease patients
- Fri Aug 21
Beats Roche, Boehringer to win best reputation among rare disease patients, but it is Viatris’ meteoric rise that makes it one to watch.
Read more -
Indian PR giant buys control of SenateSHJ
- Fri Aug 21
Adfactors PR acquires a majority stake in SenateSHJ, a major provider of media and corporate affairs services to the ANZ pharma and MedTech sectors.
Read more -
Health restructure could delay strategic negotiations
- Wed Aug 19
Blair Comley divides Health Resourcing divisions among three other groups, potentially exacerbating delays in strategic agreement negotiations.
Read more -
ANZ head’s blunt message to pharma: adapt or die
- Wed Aug 19
Outgoing Takeda GM Dave Pearce’s advice on how to survive in a sector battling local and global pressures was the highlight of NEXT Pharma’s opening session.
Read more -
Diabetes points the way to AI’s future in healthcare
- Wed Aug 19
AI is already transforming diabetes prevention, diagnosis and care, demonstrating how Australian healthcare can benefit from AI adoption.
Read more -
Rare autoimmune diseases costing $1.2B a year
- Wed Aug 19
New Patients Australia report urges faster diagnosis, better access to innovative treatments and better care pathways for two rare conditions.
Read more